Do I need a prescription for Vorasidenib 40mg tablets?

Vorasidenib 40mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Vorasidenib 40mg tablets?

Vorasidenib 40mg tablets is the generic name. It is available under brand names including: Voranigo 40mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Vorasidenib 40mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

40mg

Oral

Cytotoxic drugs

Active ingredients:

Vorasidenib

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 08.01.05

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC L01XM04

Check interactions for Vorasidenib

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Vorasidenib

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Browse all Drug Analysis Profiles A–Z

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Vorasidenib

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Vorasidenib on the MHRA register

Voranigo 40mg tablets

Servier Laboratories Ltd

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

9 similarShow details

Vorasidenib 10mg tablets

Tablet

10mg

Same therapeutic group

Ivosidenib 250mg tablets

Tablet

250mg

Same therapeutic group

Ruxolitinib 5mg/ml oral solution sugar free

Oral solution

5mg

Same BNF section

Pirtobrutinib 50mg tablets

Tablet

50mg

Same BNF section

Pirtobrutinib 100mg tablets

Tablet

100mg

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Vorasidenib

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Vorasidenib

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

45531911000001100

dm+d ID

45531911000001100

VTM (Virtual Therapeutic Moiety)

45528811000001101

VMP (Virtual Medicinal Product)

45531911000001100

BNF code

08010500

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

L01XM04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

10 days

Mechanism

Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes can be identi…

Food interactions

1 warning

Human targets

5 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

10 to 200 mg

Vorasidenib maximum plasma concentration (Cmax) and AUC increased approximately proportionally over the dose range of 10 to 200 mg (0.2…

Half-life

10 days

The mean (CV%) steady state terminal half-life is 10 days (57%).
[L51139]

Protein binding

97%

The protein binding is 97% in human plasma independent of vorasidenib concentrations in vitro.
[L51139]

Volume of distribution

930 L

The mean (CV%) volume of distribution at steady-state of vorasidenib is 3,930 L (40%).
[L51139]…

Metabolism

30%

Vorasidenib is primarily metabolized by CYP1A2 with minor contributions from CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A.…

Elimination

85%

Following a single oral radiolabeled dose of vorasidenib, 85% of the dose was recovered in feces (56% unchanged) and 4.5%…

Clearance

14 L/h

The mean (CV%) steady state oral clearance is 14 L/h (56%).
[L51139]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.[L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib].[A264209]

Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

Properties:

solid

Avg. mass: 414.74 Da

DrugBank indication

Vorasidenib is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
[L51139]

Also known as(109)

1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)-

Vorasidenib

1.1.1.42

Cytosolic NADP-isocitrate dehydrogenase

IDH

IDH1

IDPc

NADP(+)-specific ICDH

Dosage forms(6)

Tablet (Oral) — 10 mg

Tablet (Oral) — 40 mg

Tablet, film coated (Oral) — 10 mg/1

Tablet, film coated (Oral) — 10 mg

Tablet, film coated (Oral) — 40 mg/1

Tablet, film coated (Oral) — 40 mg

Molecular properties(19)

Drug interactions(521)

Known interactions with other medications. Always consult a healthcare professional.

Fluvoxamine

Moderate

DB00176

The metabolism of Vorasidenib can be decreased when combined with Fluvoxamine.

Check this interaction

Enoxacin

Moderate

DB00467

The metabolism of Vorasidenib can be decreased when combined with Enoxacin.

Check this interaction

Rofecoxib

Moderate

DB00533

The metabolism of Vorasidenib can be decreased when combined with Rofecoxib.

Check this interaction

Ciprofloxacin

Moderate

DB00537

The metabolism of Vorasidenib can be decreased when combined with Ciprofloxacin.

Check this interaction

Quinidine

Moderate

DB00908

The metabolism of Vorasidenib can be decreased when combined with Quinidine.

Check this interaction

Amiodarone

Moderate

DB01118

The metabolism of Vorasidenib can be decreased when combined with Amiodarone.

Check this interaction

Technetium Tc-99m ciprofloxacin

Moderate

DB05488

The metabolism of Vorasidenib can be decreased when combined with Technetium Tc-99m ciprofloxacin.

Check this interaction

Viloxazine

Moderate

DB09185

The metabolism of Vorasidenib can be decreased when combined with Viloxazine.

Check this interaction

Clinafloxacin

Moderate

DB14025

The metabolism of Vorasidenib can be decreased when combined with Clinafloxacin.

Check this interaction

Furafylline

Moderate

DB14029

The metabolism of Vorasidenib can be decreased when combined with Furafylline.

Check this interaction

Caffeine

Moderate

DB00201

The metabolism of Vorasidenib can be decreased when combined with Caffeine.

Check this interaction

Moxifloxacin

Moderate

DB00218

The metabolism of Vorasidenib can be decreased when combined with Moxifloxacin.

Check this interaction

Lidocaine

Moderate

DB00281

The metabolism of Vorasidenib can be decreased when combined with Lidocaine.

Check this interaction

Mexiletine

Moderate

DB00379

The metabolism of Vorasidenib can be decreased when combined with Mexiletine.

Check this interaction

Imipramine

Moderate

DB00458

The metabolism of Vorasidenib can be decreased when combined with Imipramine.

Check this interaction

Alosetron

Moderate

DB00969

The metabolism of Vorasidenib can be decreased when combined with Alosetron.

Check this interaction

Ketoconazole

Moderate

DB01026

The metabolism of Vorasidenib can be decreased when combined with Ketoconazole.

Check this interaction

Gatifloxacin

Moderate

DB01044

The metabolism of Vorasidenib can be decreased when combined with Gatifloxacin.

Check this interaction

Simeprevir

Moderate

DB06290

The metabolism of Vorasidenib can be decreased when combined with Simeprevir.

Check this interaction

Vemurafenib

Moderate

DB08881

The metabolism of Vemurafenib can be increased when combined with Vorasidenib.

Check this interaction

Zucapsaicin

Moderate

DB09120

The metabolism of Vorasidenib can be decreased when combined with Zucapsaicin.

Check this interaction

Lobeglitazone

Moderate

DB09198

The metabolism of Vorasidenib can be decreased when combined with Lobeglitazone.

Check this interaction

Curcumin

Moderate

DB11672

The metabolism of Vorasidenib can be decreased when combined with Curcumin.

Check this interaction

Pazufloxacin

Moderate

DB11774

The metabolism of Vorasidenib can be decreased when combined with Pazufloxacin.

Check this interaction

Osilodrostat

Moderate

DB11837

The metabolism of Vorasidenib can be decreased when combined with Osilodrostat.

Check this interaction

Rifampin

Moderate

DB01045

The metabolism of Vorasidenib can be increased when combined with Rifampin.

Check this interaction

Rucaparib

Moderate

DB12332

The metabolism of Vorasidenib can be increased when combined with Rucaparib.

Check this interaction

Cyclosporine

Moderate

DB00091

The metabolism of Cyclosporine can be increased when combined with Vorasidenib.

Check this interaction

Bortezomib

Moderate

DB00188

The metabolism of Bortezomib can be increased when combined with Vorasidenib.

Check this interaction

Dofetilide

Moderate

DB00204

The metabolism of Dofetilide can be increased when combined with Vorasidenib.

Check this interaction

Cabergoline

Moderate

DB00248

The metabolism of Cabergoline can be increased when combined with Vorasidenib.

Check this interaction

Theophylline

Moderate

DB00277

The metabolism of Theophylline can be increased when combined with Vorasidenib.

Check this interaction

Vindesine

Moderate

DB00309

The metabolism of Vindesine can be increased when combined with Vorasidenib.

Check this interaction

Dihydroergotamine

Moderate

DB00320

The metabolism of Dihydroergotamine can be increased when combined with Vorasidenib.

Check this interaction

Vinorelbine

Moderate

DB00361

The metabolism of Vinorelbine can be increased when combined with Vorasidenib.

Check this interaction

Sorafenib

Moderate

DB00398

The metabolism of Sorafenib can be increased when combined with Vorasidenib.

Check this interaction

Teniposide

Moderate

DB00444

The metabolism of Teniposide can be increased when combined with Vorasidenib.

Check this interaction

Erlotinib

Moderate

DB00530

The metabolism of Erlotinib can be increased when combined with Vorasidenib.

Check this interaction

Cyclophosphamide

Moderate

DB00531

The metabolism of Cyclophosphamide can be increased when combined with Vorasidenib.

Check this interaction

Nortriptyline

Moderate

DB00540

The metabolism of Nortriptyline can be increased when combined with Vorasidenib.

Check this interaction

Vincristine

Moderate

DB00541

The metabolism of Vincristine can be increased when combined with Vorasidenib.

Check this interaction

Methotrexate

Moderate

DB00563

The metabolism of Methotrexate can be increased when combined with Vorasidenib.

Check this interaction

Carbamazepine

Moderate

DB00564

The metabolism of Carbamazepine can be increased when combined with Vorasidenib.

Check this interaction

Vinblastine

Moderate

DB00570

The metabolism of Vinblastine can be increased when combined with Vorasidenib.

Check this interaction

Clonidine

Moderate

DB00575

The metabolism of Clonidine can be increased when combined with Vorasidenib.

Check this interaction

Astemizole

Moderate

DB00637

The metabolism of Astemizole can be increased when combined with Vorasidenib.

Check this interaction

Tamoxifen

Moderate

DB00675

The metabolism of Tamoxifen can be increased when combined with Vorasidenib.

Check this interaction

Warfarin

Moderate

DB00682

The metabolism of Warfarin can be increased when combined with Vorasidenib.

Check this interaction

Ergotamine

Moderate

DB00696

The metabolism of Ergotamine can be increased when combined with Vorasidenib.

Check this interaction

Irinotecan

Moderate

DB00762

The metabolism of Irinotecan can be increased when combined with Vorasidenib.

Check this interaction

Showing 50 of 521 interactions

Food & lifestyle interactions

Advice

Take with or without food. A high-fat and high-calorie increases vorasidenib and Cmax, but not to a clinically significant extent.

Toxicity & overdose

There is no information regarding the acute toxicity (LD₅₀) or overdose profile of vorasidenib.

How it works

Mechanism of action

Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes can be identified in various malignancies, including acute myeloid leukemia (AML) and gliomas.[A264209][A264214] Mutant enzymes produce an oncometabolite D-2-hydroxyglutarate (2-HG), which contributes to oncogenesis and tumour growth [A264209][A264214][A264219] by blocking the activity of α-ketoglutarate–dependent enzymes and causing epigenetic dysregulation, such as global DNA hypermethylation, and interfering with immunity.[A264214][A264219]

Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vorasidenib inhibited the IDH1 wild-type and mutant variants, including R132H and the IDH2 wild-type and mutant variants. In cell-based and in vivo tumour models expressing IDH1 or IDH2 mutated proteins, vorasidenib decreased the production of 2-2-HG and partially restored cellular differentiation.[L51139]

Pharmacodynamics

Vorasidenib works to reduce tumour growth and invasion in IDH-mutant glioma. In patients with low-grade IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next anticancer intervention.[A264224][A264229]

Vorasidenib decreases 2-HG tumour concentrations in patients with IDH1 or IDH2 mutated glioma. Relative to tumours from patients in the untreated group, the posterior median percentage reduction (95% credible interval) in tumour 2-HG was 64% (22%, 88%) to 93% (76%, 98%) in tumours from patients who received vorasidenib at exposures that were 0.3 to 0.8 times the exposure observed with the highest recommended dosage. The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of vorasidenib have not been fully characterized.[L51139]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Vorasidenib maximum plasma concentration (Cmax) and AUC increased approximately proportionally over the dose range of 10 to 200 mg (0.2 to 4 times the exposure of the highest approved recommended dosage) following once-daily administration of single and multiple doses. At the highest approved recommended dosage, steady-state mean (CV%) C_max is 133 ng/mL (73%) and AUC is 1,988 h x ng/mL (95%). A steady state is achieved within 28 days of once-daily dosing, and the mean accumulation ratio of AUC is 4.4.

The median (minimum, maximum) time to maximum plasma concentrations (T_max) at steady-state is 2 hours (0.5 to 4 hours). The mean absolute bioavailability of vorasidenib is 34%.
[L51139]

A high-fat and high-calorie (total 800-1,000 calories, of which 500-600 from fat) meal increased vorasidenib Cmax 3.1-fold and AUC 1.4-fold, compared to the fasting conditions. A low-fat and low-calorie (total 400-500 calories, of which 100-125 from fat) meal increased vorasidenib Cmax 2.3-fold and AUC 1.4-fold, compared to the fasting conditions.
[L51139]

Half-life

The mean (CV%) steady state terminal half-life is 10 days (57%).
[L51139]

Protein binding

The protein binding is 97% in human plasma independent of vorasidenib concentrations in vitro.
[L51139]

Volume of distribution

The mean (CV%) volume of distribution at steady-state of vorasidenib is 3,930 L (40%).
[L51139]
Vorasidenib penetrates the blood-brain barrier: The brain tumour-to-plasma concentration ratio is 1.6.
[L51139]

Metabolism

Vorasidenib is primarily metabolized by CYP1A2 with minor contributions from CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A. Non-CYP pathways may contribute up to 30% of its metabolism.
[L51139]
The exact metabolic pathways and metabolites have not been fully elucidated.

Route of elimination

Following a single oral radiolabeled dose of vorasidenib, 85% of the dose was recovered in feces (56% unchanged) and 4.5% was recovered in urine.
[L51139]

Clearance

The mean (CV%) steady state oral clearance is 14 L/h (56%).
[L51139]

Drug targets(5)

Proteins and enzymes this drug interacts with in the body

Isocitrate dehydrogenase [NADP] cytoplasmic

BE0001251

IDH1

inhibitor

Specific functioncadherin binding

Cellular location

Cytoplasm, cytosol

General function & pharmacology

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase .
PMID:10521434 PMID:19935646
Plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways .
PMID:10521434
May act as a corneal epithelial crystallin and may be involved in maintaining corneal epithelial transparency (By similarity)

Isocitrate dehydrogenase [NADP], mitochondrial

BE0004527

IDH2

inhibitor

Specific functionisocitrate dehydrogenase (NADP+) activity

Cellular location

Mitochondrion

General function & pharmacology

Plays a role in intermediary metabolism and energy production .
PMID:19228619 PMID:22416140
It may tightly associate or interact with the pyruvate dehydrogenase complex PMID:19228619 PMID:22416140

Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial

BE0000771

IDH3G

inhibitor

Specific functionATP binding

Cellular location

Mitochondrion

General function & pharmacology

Regulatory subunit which plays a role in the allosteric regulation of the enzyme catalyzing the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers

Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial

BE0000559

IDH3B

inhibitor

Specific functionelectron transfer activity

Cellular location

Mitochondrion

General function & pharmacology

Plays a structural role to facilitate the assembly and ensure the full activity of the enzyme catalyzing the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers

Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial

BE0000011

IDH3A

inhibitor

Specific functionisocitrate dehydrogenase (NAD+) activity

Cellular location

Mitochondrion

General function & pharmacology

Catalytic subunit of the enzyme which catalyzes the decarboxylation of isocitrate (ICT) into alpha-ketoglutarate. The heterodimer composed of the alpha (IDH3A) and beta (IDH3B) subunits and the heterodimer composed of the alpha (IDH3A) and gamma (IDH3G) subunits, have considerable basal activity but the full activity of the heterotetramer (containing two subunits of IDH3A, one of IDH3B and one of IDH3G) requires the assembly and cooperative function of both heterodimers

Metabolizing enzymes(8)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP2B6Cytochrome P450 2B6

substrate

inducer

CYP2C8Cytochrome P450 2C8

substrate

inducer

CYP2C9Cytochrome P450 2C9

substrate

inducer

CYP2C19Cytochrome P450 2C19

substrate

inducer

CYP2D6Cytochrome P450 2D6

substrate

CYP3A4Cytochrome P450 3A4

substrate

inducer

UGT1A4UDP-glucuronosyltransferase 1A4

inducer

Transporters(1)

Proteins that transport this drug across cell membranes

Broad substrate specificity ATP-binding cassette transporter ABCG2

BE0001067

ABCG2

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells .
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562

Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388

In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239

Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).

Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042

In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).

In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response

Scientific references(5)

Konteatis Z., Artin E., Nicolay B., Straley K., Padyana A.K., Jin L., Chen Y., Narayaraswamy R., Tong S., Wang F., Zhou D., Cui D., Cai Z., Luo Z., Fang C., Tang H., Lv X., Nagaraja R., Yang H., Su S.M., Sui Z., Dang L., Yen K., Popovici-Muller J., Codega P., Campos C., Mellinghoff I.K., Biller S.A.

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.

ACS Medicine Chemistry Lett

2020 Jan 2211(2):101-107. doi: 10.1021/acsmedchemlett.9b00509. eCollection 2020 Feb 13

PMID: 32071674 DOI: 10.1021/acsmedchemlett.9b00509

Mellinghoff I.K., Penas-Prado M., Peters K.B., Burris HA 3rd, Maher E.A., Janku F., Cote G.M., de la Fuente M.I., Clarke J.L., Ellingson B.M., Chun S., Young R.J., Liu H., Choe S., Lu M., Le K., Hassan I., Steelman L., Pandya S.S., Cloughesy T.F., Wen P.Y.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Clinical Cancer Research

2021 Aug 1527(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2

PMID: 34078652 DOI: 10.1158/1078-0432.CCR-21-0611

Ruda R., Horbinski C., van den Bent M., Preusser M., Soffietti R.

IDH inhibition in gliomas: from preclinical models to clinical trials.

Nature Review Neurology

2024 Jul20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17

PMID: 38760442 DOI: 10.1038/s41582-024-00967-7

Bombino A., Magnani M., Conti A.

A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma. Curr Mol Pharmacol. 2024 Feb 29.

doi: 10

2174/0118761429290327240222061812

PMID: 38425121 DOI: 10.2174/0118761429290327240222061812

Mellinghoff I.K., van den Bent M.J., Blumenthal D.T., Touat M., Peters K.B., Clarke J., Mendez J., Yust-Katz S., Welsh L., Mason W.P., Ducray F., Umemura Y., Nabors B., Holdhoff M., Hottinger A.F., Arakawa Y., Sepulveda J.M., Wick W., Soffietti R., Perry J.R., Giglio P., de la Fuente M., Maher E.A., Schoenfeld S., Zhao D., Pandya S.S., Steelman L., Hassan I., Wen P.Y., Cloughesy T.F.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

New England Journal of Medicine

2023 Aug 17389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4

PMID: 37272516 DOI: 10.1056/NEJMoa2304194

ATC classification(1 code)

ATC L01XM04

Salt forms(2)

Vorasidenib citrate(DBSALT003529)

Vorasidenib citrate anhydrous(DBSALT003528)

Protein Data Bank entries(4)

Commercial products(6)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Vorasidenib

DB17097

CAS number

1644545-52-7

UNII (FDA)

789Q85GA8P

InChI Key (molecular fingerprint)

QCZAWDGAVJMPTA-RNFRBKRXSA-N

Additional database identifiers

Drugs Product Database (DPD)

24002

ChemSpider

64835242

BindingDB

279948

PDB

9UO

Wikipedia

Vorasidenib

ChEMBL

CHEMBL4279047

RxCUI

2690647

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5382

GenAtlas

IDH1

GeneCards

IDH1

GenBank Gene Database

AF020038

GenBank Protein Database

3641398

Guide to Pharmacology

2884

UniProtKB

O75874

UniProt Accession

IDHC_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5383

GeneCards

IDH2

Guide to Pharmacology

2885

UniProtKB

P48735

UniProt Accession

IDHP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5386

GenAtlas

IDH3G

GeneCards

IDH3G

GenBank Gene Database

Z68907

GenBank Protein Database

1167849

UniProtKB

P51553

UniProt Accession

IDH3G_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5385

GenAtlas

IDH3B

GeneCards

IDH3B

GenBank Gene Database

U49283

GenBank Protein Database

2737886

UniProtKB

O43837

UniProt Accession

IDH3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5384

GenAtlas

IDH3A

GeneCards

IDH3A

GenBank Gene Database

U07681

GenBank Protein Database

706839

UniProtKB

P50213

UniProt Accession

IDH3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12536

GeneCards

UGT1A4

GenBank Gene Database

M57951

GenBank Protein Database

184475

UniProtKB

P22310

UniProt Accession

UD14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:74

GenAtlas

ABCG2

GeneCards

ABCG2

GenBank Gene Database

AF103796

GenBank Protein Database

4185796

Guide to Pharmacology

792

UniProtKB

Q9UNQ0

UniProt Accession

ABCG2_HUMAN

Patent information

5 active patents

11345677

United States

Approved 31 May 2022 · Expires 16 Jan 2039

12y 9m

11844758

United States

Approved 19 Dec 2023 · Expires 4 Dec 2035

9y 8m

9579324

United States

Approved 28 Feb 2017 · Expires 11 Jul 2034

8y 3m

10172864

United States

Approved 8 Jan 2019 · Expires 11 Jul 2034

8y 3m

12433895

United States

Approved 11 Jul 2014 · Expires 11 Jul 2034

8y 3m

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Vorasidenib 40mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
14

Chemical identifiers

Vorasidenib

Additional database identifiers

Patent information

DrugBank citations

Vorasidenib 40mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science14

Chemical identifiers

Vorasidenib

Additional database identifiers

Patent information

DrugBank citations

Deep science
14